Status:

COMPLETED

Pharmacokinetics and Safety Profile of Digoxin in Infants With Single Ventricle Congenital Heart Disease

Lead Sponsor:

Christoph P Hornik, MD MPH

Collaborating Sponsors:

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

The Emmes Company, LLC

Conditions:

Congenital Heart Disease

Eligibility:

All Genders

Up to 6 years

Brief Summary

This is a prospective, multi-center, open-label, PK and safety profile study of enteral digoxin in children \<6 months old at time of enrollment, post-surgical or hybrid stage 1 palliation, but prior ...

Detailed Description

The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) funded this protocol titled "Pharmacokinetics and Safety Profile of Digoxin in Infants with Single Ventricle...

Eligibility Criteria

Inclusion

  • Diagnosis of single ventricle congenital heart disease
  • Status post-surgical or hybrid stage 1 palliation but prior to surgical stage 2 palliation
  • Age ≤ 30 days of life at time of stage 1 palliation
  • Age \< 6 months at time of enrollment
  • Require treatment with enteral digoxin per their treating medical provider if their planned maintenance treatment dosing regimen is within the labeled dose range of 7.5 - 20 mcg/kg/day divided in 2 or 3 equal doses
  • Informed consent from parent(s) or legal guardian(s)

Exclusion

  • Serum creatinine \> 2 mg/dL at enrollment
  • Diagnosis of second degree or higher atrioventricular conduction block at enrollment
  • Diagnosis of clinically significant sinus bradycardia requiring intervention at enrollment
  • Known hypersensitivity to digoxin or other forms of digitalis
  • Extracorporeal life support (i.e., ECMO, dialysis, ventricular assist device) at enrollment
  • Received digoxin prior to enrollment
  • Received or anticipated to receive a loading dose of digoxin.
  • Any condition that would make the participant, in the opinion of the investigator, unsuitable for the study

Key Trial Info

Start Date :

August 5 2019

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

January 17 2022

Estimated Enrollment :

50 Patients enrolled

Trial Details

Trial ID

NCT03877965

Start Date

August 5 2019

End Date

January 17 2022

Last Update

October 12 2022

Active Locations (11)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 3 (11 locations)

1

Mattel Children's Hospital at UCLA

Los Angeles, California, United States, 90095

2

Rady Childrens Hospital and Health Center

San Diego, California, United States, 92123

3

The Children's Hospital Colorado

Aurora, Colorado, United States, 80045

4

Alfred I. DuPont Hospital for Children

Wilmington, Delaware, United States, 19803